Dr. Moseley’s current role is that of internal advisor to Business Development and New Ventures at Guidant with the goal of strategically moving the device focus into convergence with pharma and biologics innovation. Before joining Guidant, Dr. Moseley was the CEO of Cognate Therapeutics, a startup cellular therapy company developing bone marrow stromal cells, and other stem cell technologies. Prior to the founding of Cognate, Dr. Moseley was the CEO of Osiris Therapeutics, Inc, an adult mesenchymal stem cell company. While she was at Osiris, the company led the stem cell development field with over 4 new INDs in multiple therapeutic areas. Dr. Moseley has been involved in development of biological products such as antibodies, gene and cell therapies for over 12 years with companies such as AIS/Aventis and Systemix/Novartis.
Dr. Moseley’s early corporate experience focused extensively on clinical and product development of applications of antibodies in immunotherapy, blood stem cell therapies and cancer vaccines with therapeutic areas in oncology, transplantation, and infectious disease. Over recent years, she initiated the development of mesenchymal stem cell therapies with emphasis on oncology, transplantation and connective tissue disorders, including arthritis and bone disorders. Her regulatory experience has primarily been in biologics and CDRH as applied to antibody, devices and cell-based product development, but she has also filed INDs with CDER as well. Responsibilities have also encompassed product development, quality control and quality assurance, and provided a basis for the management of a research/development stage companies.
Dr. Moseley is currently an advisor to the Canadian Stem Cell Network, as well as a member of the scientific advisory board for Stryker Orthopedics. She is also a reviewer for the Journal of Bone and Joint Surgery. Licensed in the State of Texas, she also is a member of the American Heart Association, the American Society of Hematology and AMA.
